Identification of Potential Biomarkers of Chronic Kidney Disease in Individuals with Diabetes: Protocol for a Cross-sectional Observational Study.
chronic kidney disease
diabetes
epigenetics
gut microbiome
metabolomics
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
31 Jul 2020
31 Jul 2020
Historique:
received:
16
09
2019
accepted:
12
05
2020
revised:
03
05
2020
entrez:
1
8
2020
pubmed:
1
8
2020
medline:
1
8
2020
Statut:
epublish
Résumé
The importance of identifying people with diabetes and progressive kidney dysfunction relates to the excess morbidity and mortality of this group. Rates of cardiovascular disease are much higher in people with both diabetes and kidney dysfunction than in those with only one of these conditions. By the time these people are identified in current clinical practice, proteinuria and renal dysfunction are already established, limiting the effectiveness of therapeutic interventions. The identification of an epigenetic or blood metabolite signature or gut microbiome profile may identify those with diabetes at risk of progressive chronic kidney disease, in turn providing targeted intervention to improve patient outcomes. This study aims to identify potential biomarkers in people with diabetes and chronic kidney disease (CKD) associated with progressive renal injury and to distinguish between stages of chronic kidney disease. Three sources of biomarkers will be explored, including DNA methylation profiles in blood lymphocytes, the metabolomic profile of blood-derived plasma and urine, and the gut microbiome. The cross-sectional study recruited 121 people with diabetes and varying stages (stages 1-5) of chronic kidney disease. Single-point data collection included blood, urine, and fecal samples in addition to clinical data such as anthropometric measurements and biochemical parameters. Additional information obtained from medical records included patient demographics, medical comorbidities, and medications. Data collection commenced in January 2018 and was completed in June 2018. At the time of submission, 121 patients had been recruited, and 119 samples remained after quality control. There were 83 participants in the early diabetes-associated CKD group with a mean estimated glomerular filtration rate (eGFR) of 61.2 mL/min/1.73 m2 (early CKD group consisting of stage 1, 2, and 3a CKD), and 36 participants in the late diabetic CKD group with a mean eGFR of 23.9 mL/min/1.73 m2 (late CKD group, consisting of stage 3b, 4, and 5), P<.001. We have successfully obtained DNA for methylation and microbiome analyses using the biospecimens collected via this protocol and are currently analyzing these results together with the metabolome of this cohort of individuals with diabetic CKD. Recent advances have improved our understanding of the epigenome, metabolomics, and the influence of the gut microbiome on the incidence of diseases such as cancers, particularly those related to environmental exposures. However, there is a paucity of literature surrounding these influencers in renal disease. This study will provide insight into the fundamental understanding of the pathophysiology of CKD in individuals with diabetes, especially in novel areas such as epigenetics, metabolomics, and the kidney-gut axis. DERR1-10.2196/16277.
Sections du résumé
BACKGROUND
BACKGROUND
The importance of identifying people with diabetes and progressive kidney dysfunction relates to the excess morbidity and mortality of this group. Rates of cardiovascular disease are much higher in people with both diabetes and kidney dysfunction than in those with only one of these conditions. By the time these people are identified in current clinical practice, proteinuria and renal dysfunction are already established, limiting the effectiveness of therapeutic interventions. The identification of an epigenetic or blood metabolite signature or gut microbiome profile may identify those with diabetes at risk of progressive chronic kidney disease, in turn providing targeted intervention to improve patient outcomes.
OBJECTIVE
OBJECTIVE
This study aims to identify potential biomarkers in people with diabetes and chronic kidney disease (CKD) associated with progressive renal injury and to distinguish between stages of chronic kidney disease. Three sources of biomarkers will be explored, including DNA methylation profiles in blood lymphocytes, the metabolomic profile of blood-derived plasma and urine, and the gut microbiome.
METHODS
METHODS
The cross-sectional study recruited 121 people with diabetes and varying stages (stages 1-5) of chronic kidney disease. Single-point data collection included blood, urine, and fecal samples in addition to clinical data such as anthropometric measurements and biochemical parameters. Additional information obtained from medical records included patient demographics, medical comorbidities, and medications.
RESULTS
RESULTS
Data collection commenced in January 2018 and was completed in June 2018. At the time of submission, 121 patients had been recruited, and 119 samples remained after quality control. There were 83 participants in the early diabetes-associated CKD group with a mean estimated glomerular filtration rate (eGFR) of 61.2 mL/min/1.73 m2 (early CKD group consisting of stage 1, 2, and 3a CKD), and 36 participants in the late diabetic CKD group with a mean eGFR of 23.9 mL/min/1.73 m2 (late CKD group, consisting of stage 3b, 4, and 5), P<.001. We have successfully obtained DNA for methylation and microbiome analyses using the biospecimens collected via this protocol and are currently analyzing these results together with the metabolome of this cohort of individuals with diabetic CKD.
CONCLUSIONS
CONCLUSIONS
Recent advances have improved our understanding of the epigenome, metabolomics, and the influence of the gut microbiome on the incidence of diseases such as cancers, particularly those related to environmental exposures. However, there is a paucity of literature surrounding these influencers in renal disease. This study will provide insight into the fundamental understanding of the pathophysiology of CKD in individuals with diabetes, especially in novel areas such as epigenetics, metabolomics, and the kidney-gut axis.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
DERR1-10.2196/16277.
Identifiants
pubmed: 32734931
pii: v9i7e16277
doi: 10.2196/16277
pmc: PMC7428908
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e16277Informations de copyright
©Ashani R Lecamwasam, Mohammadreza Mohebbi, Elif I Ekinci, Karen M Dwyer, Richard Saffery. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 31.07.2020.
Références
Clin Exp Pharmacol Physiol. 2011 Jul;38(7):451-9
pubmed: 21309809
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
Angew Chem Int Ed Engl. 2003 Jul 28;42(29):3340-63
pubmed: 12888958
Am J Physiol Renal Physiol. 2010 Jul;299(1):F14-25
pubmed: 20462972
Bioinformatics. 2010 Oct 1;26(19):2460-1
pubmed: 20709691
Kidney Int. 2013 Feb;83(2):308-15
pubmed: 22992469
Am J Nephrol. 2016;43(5):366-74
pubmed: 27172772
Mamm Genome. 2009 Sep-Oct;20(9-10):624-32
pubmed: 19697079
Bioinformatics. 2014 Mar 1;30(5):614-20
pubmed: 24142950
Nat Rev Nephrol. 2014 Sep;10(9):517-30
pubmed: 25003613
Curr Opin Nephrol Hypertens. 2015 Jul;24(4):371-9
pubmed: 26050125
Diabetes. 2009 Dec;58(12):2718-25
pubmed: 19940235
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
Nat Commun. 2018 Aug 17;9(1):3308
pubmed: 30120223
Bioinformatics. 2011 Aug 15;27(16):2194-200
pubmed: 21700674
Nat Methods. 2013 Oct;10(10):996-8
pubmed: 23955772
Appl Environ Microbiol. 2006 Jul;72(7):5069-72
pubmed: 16820507
Cardiovasc Res. 2011 Jun 1;90(3):421-9
pubmed: 21266525
Genome Biol. 2016 Oct 7;17(1):208
pubmed: 27717381
Biochem Biophys Res Commun. 2009 Jun 12;383(4):421-5
pubmed: 19364493
Arch Intern Med. 2004 Mar 22;164(6):659-63
pubmed: 15037495